X

Trial Profile

Idarubicin and Cladribine in Recurrent and Refractory Acute Myeloid Leukemia: A POG Phase II Study.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cladribine (Primary) ; Idarubicin (Primary) ; Filgrastim
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; Therapeutic Use

Most Recent Events

05 Oct 2009 New source identified and integrated (New Jersey Cancer Trial Connect).
05 Oct 2009 Additional lead trial investigators Harris M and Kamalakar P identified as reported by New Jersey Cancer Trial Connect.
17 Feb 2009 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov, last updated 17-Feb-2009.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com